Peking University Third Hospital Team Led by Zhang Weilong and Collaborators Publish in American Journal of Hematology, Systematically Analyzing Risk Factors and Risk Stratification for CAR-T Cell Therapy-Associated Hemophagocytic Lymphohistiocytosis

Author: Zhang Weilong

https://www.puh3.net.cn/info/1971/173931.htm

On May 6, the team led by Zhang Weilong from the Department of Hematology of Peking University Third Hospital, in collaboration with the team led by Peng Qin from the First Affiliated Hospital of Gannan Medical University, published a systematic review and meta-analysis titled "Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis" online in the authoritative international hematology journal American Journal of Hematology.

This study is currently the largest and most systematic evidence-based medical study worldwide on hemophagocytic lymphohistiocytosis after CAR-T cell therapy. It is the first to comprehensively quantify the clinical characteristics and core risk factors of this fatal complication, providing important clinical evidence for full-process safety management of CAR-T therapy and precise prevention and control in high-risk populations.

Zhang Changhui from Peking University Third Hospital and the First Clinical Medical College of Gannan Medical University, and Wu Hongyan from the First Clinical Medical College of Gannan Medical University, are co-first authors. Peng Qin and Zhang Weilong are co-corresponding authors.

Screenshot of the Paper

Original Link: https://doi.org/10.1002/ajh.70351